Hepatic steatosis and type 2 diabetes

Current and future treatment considerations

John Richard, Ildiko Lingvay

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Hepatic steatosis, considered the first step in the pathophysiologic continuum of non-alcoholic fatty liver disease, is estimated to afflict 30% of the US population and over 75% of patients with Type 2 diabetes. Given the expected rise in the prevalence of obesity and Type 2 diabetes in the following decades, hepatic steatosis will, if not already, become an epidemic. The consequences of hepatic steatosis are numerous, and range from progression to chronic liver disease, with its associated morbidity and mortality, to worsening insulin resistance and Type 2 diabetes, as well as being an independent contributor to cardiovascular disease. All such consequences are more likely to occur in patients with Type 2 diabetes who are already at high risk of cardiovascular events. In this article we review the evidence behind the available therapeutic options for hepatic steatosis, and identify challenges and unmet needs in the field.

Original languageEnglish (US)
Pages (from-to)321-328
Number of pages8
JournalExpert Review of Cardiovascular Therapy
Volume9
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Type 2 Diabetes Mellitus
Liver
Therapeutics
Insulin Resistance
Liver Diseases
Chronic Disease
Cardiovascular Diseases
Obesity
Morbidity
Mortality
Population

Keywords

  • FXR agonists
  • hepatic steatosis
  • incretin mimetics
  • metabolic syndrome
  • metformin
  • non-alcoholic fatty liver disease
  • obesity
  • thiazolidinediones
  • Type 2 diabetes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Hepatic steatosis and type 2 diabetes : Current and future treatment considerations. / Richard, John; Lingvay, Ildiko.

In: Expert Review of Cardiovascular Therapy, Vol. 9, No. 3, 03.2011, p. 321-328.

Research output: Contribution to journalArticle

@article{8e1d4be741ea42d69ca0610a39896920,
title = "Hepatic steatosis and type 2 diabetes: Current and future treatment considerations",
abstract = "Hepatic steatosis, considered the first step in the pathophysiologic continuum of non-alcoholic fatty liver disease, is estimated to afflict 30{\%} of the US population and over 75{\%} of patients with Type 2 diabetes. Given the expected rise in the prevalence of obesity and Type 2 diabetes in the following decades, hepatic steatosis will, if not already, become an epidemic. The consequences of hepatic steatosis are numerous, and range from progression to chronic liver disease, with its associated morbidity and mortality, to worsening insulin resistance and Type 2 diabetes, as well as being an independent contributor to cardiovascular disease. All such consequences are more likely to occur in patients with Type 2 diabetes who are already at high risk of cardiovascular events. In this article we review the evidence behind the available therapeutic options for hepatic steatosis, and identify challenges and unmet needs in the field.",
keywords = "FXR agonists, hepatic steatosis, incretin mimetics, metabolic syndrome, metformin, non-alcoholic fatty liver disease, obesity, thiazolidinediones, Type 2 diabetes",
author = "John Richard and Ildiko Lingvay",
year = "2011",
month = "3",
doi = "10.1586/erc.11.15",
language = "English (US)",
volume = "9",
pages = "321--328",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Hepatic steatosis and type 2 diabetes

T2 - Current and future treatment considerations

AU - Richard, John

AU - Lingvay, Ildiko

PY - 2011/3

Y1 - 2011/3

N2 - Hepatic steatosis, considered the first step in the pathophysiologic continuum of non-alcoholic fatty liver disease, is estimated to afflict 30% of the US population and over 75% of patients with Type 2 diabetes. Given the expected rise in the prevalence of obesity and Type 2 diabetes in the following decades, hepatic steatosis will, if not already, become an epidemic. The consequences of hepatic steatosis are numerous, and range from progression to chronic liver disease, with its associated morbidity and mortality, to worsening insulin resistance and Type 2 diabetes, as well as being an independent contributor to cardiovascular disease. All such consequences are more likely to occur in patients with Type 2 diabetes who are already at high risk of cardiovascular events. In this article we review the evidence behind the available therapeutic options for hepatic steatosis, and identify challenges and unmet needs in the field.

AB - Hepatic steatosis, considered the first step in the pathophysiologic continuum of non-alcoholic fatty liver disease, is estimated to afflict 30% of the US population and over 75% of patients with Type 2 diabetes. Given the expected rise in the prevalence of obesity and Type 2 diabetes in the following decades, hepatic steatosis will, if not already, become an epidemic. The consequences of hepatic steatosis are numerous, and range from progression to chronic liver disease, with its associated morbidity and mortality, to worsening insulin resistance and Type 2 diabetes, as well as being an independent contributor to cardiovascular disease. All such consequences are more likely to occur in patients with Type 2 diabetes who are already at high risk of cardiovascular events. In this article we review the evidence behind the available therapeutic options for hepatic steatosis, and identify challenges and unmet needs in the field.

KW - FXR agonists

KW - hepatic steatosis

KW - incretin mimetics

KW - metabolic syndrome

KW - metformin

KW - non-alcoholic fatty liver disease

KW - obesity

KW - thiazolidinediones

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=79953246834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953246834&partnerID=8YFLogxK

U2 - 10.1586/erc.11.15

DO - 10.1586/erc.11.15

M3 - Article

VL - 9

SP - 321

EP - 328

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 3

ER -